By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cellectar Biosciences (Formerly Known As Novelos Therapeutics, Inc.)  

3301 Agriculture Drive

Madison  Wisconsin  53716  U.S.A.
Phone: 608-441-8120 Fax: 608-441-8120


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: Cellectar Biosciences
Employees:
Symbol: CLRB
 



Industry
Pharmaceutical

Segment
Drug Discovery





Company News
Upon Successful Completion Of Cohort 3, Cellectar Biosciences  (CLRB) Initiates Fourth Cohort Of Its Phase I Clinical Trial Of CLR 131 In Multiple Myeloma 2/22/2017 10:39:37 AM
Cellectar Biosciences  (CLRB) Announces Two Peer Reviewed Studies Demonstrating The Capabilities Of The PDC Platform 1/31/2017 7:21:22 AM
Cellectar Biosciences  (CLRB) Release: Company Announces Additional U.S. Patent Granted For CLR 131 And CLR 125 In A Broad Range Of Solid Tumors 1/24/2017 7:17:19 AM
Cellectar Biosciences  (CLRB) Announces US And Japanese Patent Allowances For Diagnostic And Optical Imaging PDCs 12/20/2016 9:45:04 AM
Cellectar Biosciences  (CLRB) Announces USPTO Grants Patent Allowances For Radiotherapeutic Pdcs For A Variety Of Solid Tumor Types 12/14/2016 6:52:34 AM
Cellectar Biosciences  (CLRB) Announces USPTO Grants Patent For Paclitaxel PDC; Provides Additional Patent Protection For Select Solid Tumors Through 2035 12/12/2016 7:31:43 AM
Cellectar Biosciences  (CLRB) Presents Poster At The 58th Annual Meeting Of The American Society of Hematology 12/6/2016 7:42:42 AM
Cellectar Biosciences  (CLRB) Announces Results From The First Two Cohorts Of Its CLR 131 Phase I Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, And Progression Free Survival Similar To Or Better Than Recently Approved Therapies 12/1/2016 7:14:59 AM
Cellectar Biosciences  (CLRB) Announces Successful Completion Of $9.2 Million Public Offering, Which Includes Full Exercise Of $1.2 Million Over-Allotment Option 11/30/2016 8:10:52 AM
Cellectar Biosciences  (CLRB) Announces Partnership With Radiopharmaceutical Specialists, CPDC, To Establish Manufacturing Capacity In Anticipation Of CLR 131 Pivotal Trial And Commercial Production 11/28/2016 7:16:06 AM
12345678910...
//-->